Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interferon beta-1b - Nuron Biotech

Drug Profile

Interferon beta-1b - Nuron Biotech

Alternative Names: BaroFeron; Interferon beta-1b - Nuron Biotech/BaroFold; NU-100; Recombinant human interferon beta - BaroFold/Nuron Biotech; Relonsiv

Latest Information Update: 30 Apr 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BaroFold
  • Developer Nuron Biotech
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Immunomodulators; Interferon beta stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Multiple sclerosis

Most Recent Events

  • 13 Nov 2012 Nuron Biotech completes enrolment in its phase III trial for Multiple sclerosis in Italy, Bulgaria, Hungary, Poland, Spain, Belarus, Croatia, Georgia, Serbia, Ukraine, Russia & Lebanon (NCT01464905)
  • 31 Oct 2011 Phase-III clinical trials in Multiple sclerosis in Bulgaria (SC)
  • 31 Oct 2011 Phase-III clinical trials in Multiple sclerosis in Croatia (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top